U.S. Food and Drug Administration. Accelerated approval. 2023. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval. Accessed 10 July 2023.

U.S. Food and Drug Administration CDER Accelerated Approval Program Database. 2023. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program. Accessed 10 July 2023.

Sachs RE, Donohue JM, Dusetzina SB. Accelerated approval—taking the FDA’s concerns seriously. N Engl J Med. 2022;387(3):199–201. https://doi.org/10.1056/NEJMp2204487.

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA; FDA. 2020. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy. Accessed 10 July 2023.

U.S. Food and Drug Administration. FDA Commissioner and Chief Scientist announce decision to withdraw approval of Makena. 2023. https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena. Accessed 10 July 2023.

Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther. 2017;11:533–45. https://doi.org/10.2147/DDDT.S97635.

Article  CAS  Google Scholar 

Sarepta Therapeutics, Inc. 2023. https://investorrelations.sarepta.com/sec-filings. Accessed 10 July 2023.

Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut. Bloomberg.com. 2023. https://www.bloomberg.com/news/articles/2023-05-14/fda-fast-tracked-drugs-make-companies-billions-on-unproven-claims. Accessed 7 Sept 2023.

Sarepta Therapeutics, Inc. A randomized, double-blind, dose finding and comparison study of the safety and efficacy of a high dose of eteplirsen, preceded by an open-label dose escalation, in patients with Duchenne muscular dystrophy with deletion mutations amenable to exon 51 skipping (Clinical Trial Registration No. NCT03992430). clinicaltrials.gov. 2023. https://clinicaltrials.gov/ct2/show/NCT03992430. Accessed 10 July 2023.

Ballreich J, Socal M, Bennett CL, Schoen MW, Trujillo A, Xuan A, Anderson G. Medicare spending on drugs with accelerated approval. Ann Intern Med. 2022;175(7):938–44. https://doi.org/10.7326/M21-4442.

Article  PubMed  Google Scholar 

Centers for Medicare & Medicaid Services. 2023. https://www.cms.gov/newsroom/press-releases/hhs-secretary-responds-presidents-executive-order-drug-prices. Retrieved 6 June 2023.

Reardon S. ‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work? Nature. 2023. https://doi.org/10.1038/d41586-023-01799-z.

Article  PubMed  Google Scholar 

Teemkin E, Trin J, King, Spaling LLLP. FDA’S accelerated approval pathway: a rare disease perspective. https://rarediseases.org/?s=accelerated+approval. Retrieved 8 Sept 2023.

Cooley LP. FDORA changes to the FDA accelerated approval program. 2023. https://www.cooley.com/news/insight/2023/2023-01-31-fdora-changes-to-the-fda-accelerated-approval-program#:~:text=Enacted%20on%20December%2029%2C%202022,authority%20in%20several%20key%20areas. Accessed 7 Sept 2023.

Lupkin, S. FDA has new leverage over companies looking for a quicker drug approval. NPR. 2023. https://www.npr.org/sections/health-shots/2023/03/03/1160702899/fda-enforcement-drug-approval-manufacturer-promises. Accessed 7 Sept 2023.